Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL627 versus octocog alfa in previously treated patients with severe hemophilia A
NL-OMON40376Phase 3Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of lonoctocog alfa in hemophilia A (2 arms), sponsored by CSL Limited. Primary endpoints: Treatment success rate for bleeding episodes, Surgical treatment success rate and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
lonoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON40376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40376.